Tag Archives: Glantz

NYT calls Trump a liar; critics fail to make it so clear about Glantz

[Update: For those who want more details of the criticism of the Dutra-Glantz paper, or are only interested in that and not the broader question of how to combat lies, I have posted a PubMed Commons comment here.]

Further on the critically important theme of my previous post, we are perhaps already starting to see a positive trend. The New York Times went as far as to identify one of Trump’s lies with the word “lie” in its top headline today. They did not go quite so far as to label him a “liar”, understandably, but that is implicit. Readers of this blog will recall my arguments for the importance of calling out liars as such. Piecemeal responses to each individual lie are a hopeless tactic and not effective. For one thing, you end up with this problem: Continue reading

Feynman vs. Public Health (Rodu vs. Glantz)

by Carl V Phillips

I started rereading Richard Feynman’s corpus on how to think about and do science. Actually I started by listening to an audiobook of one of his collected works because I had to clear my palate, as it were, after listening to a lecture series from one of those famous self-styled “skeptic” “debunkers”. I tried to force myself to finish it, but could not. For the most part, those pop science “explainer” guys merely replace some of the errors they are criticizing with other errors, and actually repeat many of the exact same errors. The only reason they make a better case than those they choose to criticize is that the latter are so absurd (at least in the strawman versions the “skeptics” concoct) that it is hard to fail.

Feynman made every legitimate point these people make, with far more precision and depth. Continue reading

An old letter to the editor about Glantz’s ad hominems

by Carl V Phillips

I am going through some of my old files of unpublished (or, more often, only obscurely published) material, and though I would post some of it. While I suspect you will find this a poor substitute for my usual posts, I hope there is some interest (and implicit lessons for those who think any of this is new), and posting a few of these will keep this blog going for a few weeks.

This one, from 2009, was written as a letter to the editor (rejected by the journal — surprise!) by my team at the University of Alberta School of Public Health. It was about this rant, “Tobacco Industry Efforts to Undermine Policy-Relevant Research” by Stanton Glantz and one of his deluded minions, Anne Landman, published in the American Journal of Public Health (non-paywalled version if for some unfathomable reason you actually want to read it). The authorship of our letter was Catherine M Nissen, Karyn K Heavner, me, and Lisa Cockburn. 

The letter read:


Landman and Glantz’s paper in the January 2009 issue of AJPH is a litany of ad hominem attacks on those who have been critical of Glantz’s work, with no actual defense of that work. This paper seems to be based on the assumption that a researcher’s criticism should be dismissed if it is possible to identify funding that might have motivated the criticism. However, for this to be true it must be that: (1) there is such funding, (2) there is reason to believe the funding motivated the criticism, and (3) the criticism does not stand on its own merit. The authors devote a full 10 pages to (1), but largely ignore the key logical connection, (2). This is critical because if we step back and look at the motives of funders (rather than just using funding as an excuse for ignoring our opponents), we see that researchers tend to get funding from parties that are interested in their research, even if the researcher did not seek funding from that party (Marlow, 2008).

Most important, the authors completely ignore (3). Biased motives (whether related to funding or not) can certainly make us nervous that authors have cited references selectively, or in an epidemiology study have chopped away years of data to exaggerate an estimated association, or have otherwise hidden something. [Note: In case it is not obvious, these are subtle references to Glantz’s own methods.] But a transparent valid critique is obviously not impeached by claims of bias. The article’s only defense against the allegation that Glantz’s reporting “was uncritical, unsupportable and unbalanced” is to point to supposed “conflicts of interest” of the critics. If Glantz had an argument for why his estimates are superior to the many competing estimates or why the critiques were wrong, this would seem a convenient forum for this defense, but no such argument appears. Rather, throughout this paper it seems the reader is expected to assume that Glantz’s research is infallible, and that any critiques are unfounded. This is never the case with any research conducted, and surely the authors must be aware that any published work is open to criticism.

Indeed, presumably there are those who disagree with Glantz’s estimates who conform to his personal opinions about who a researcher should be taking funding from, and yet we see no response to them. For example, even official statistics that accept the orthodoxy about second hand smoke include a wide range of estimates (e.g., the California Environmental Protection Agency (2005) estimated it causes 22,700-69,600 cardiac deaths per year), and much of the range implies Glantz’s estimates are wrong. But in a classic example of “a-cell epidemiology” [Note: This is a metaphoric reference to the 2×2 table of exposure status vs. disease status; the cell counting individuals with the exposure and the disease is usually labeled “a”.], Glantz has collected exposed cases to report, but tells us nothing of his critics who are not conveniently vulnerable to ad hominem attacks.

It is quite remarkable that given world history, and not least the recent years in the U.S., people seem willing to accept government as unbiased and its claims as infallible. Governments are often guilty of manipulating research (Kempner, 2008). A search of the Computer Retrieval of Information on Scientific Projects database (http://report.nih.gov/crisp/CRISPQuery.aspx) on the National Institute of Health’s website found that one of the aims of the NCI grant that funded Landman and Glantz’s research (specified in their acknowledgement statement) is to “Continue to describe and assess the tobacco industry’s evolving strategies to influence the conduct, interpretation, and dissemination of science and how the industry has used these strategies to oppose tobacco control policies.” Cleary this grant governs not only the topic but also the conclusions of the research, a priori concluding that the tobacco industry continues to manipulate research, and motivating the researcher to write papers that support this. Surely it is difficult to imagine a clearer conflict of interest than, “I took funding that required me to try to reach a particular conclusion.”

The comment “[t]hese efforts can influence the policymaking process by silencing voices critical of tobacco industry interests and discouraging other scientists from doing research that may expose them to industry attacks” is clearly ironic. It seems to describe exactly what the authors are attempting to do to Glantz’s critics, discredit and silence them, to say nothing of Glantz’s concerted campaign to destroy the career of one researcher whose major study produced a result Glantz did not like (Enstrom, 2007; Phillips, 2008). If Glantz were really interested in improving science and public health, rather than defending what he considers to be his personal turf, he would spend his time explaining why his numbers are better. Instead, he spends his time outlining (and then not even responding to) the history of critiques of his work, offering only his personal opinions about the affiliations of his critics in his defense.


1. Landman, A., and Glantz, Stanton A. Tobacco Industry Efforts to Undermine Policy-Relevant Research. American Journal of Public Health. January 2009; 99(1):1-14.

2. Marlow, ML. Honestly, Who Else Would Fund Such Research? Reflections of a Non-Smoking Scholar. Econ Journal Watch. 2008 May; 5(2):240-268.

3. California Environmental Protection Agency. Identification of Environmental Tobacco Smoke as a Toxic Air Contaminant. Executive Summary. June 2005.

4. Kempner, J. The Chilling Effect: How Do Researchers React to Controversy? PLoS Medicine 2008; 5(11):e222.

5. Enstrom, JE. Defending legitimate epidemiologic research: combating Lysenko pseudoscience. Epidemiologic Perspectives & Innovations 2007, 4:11.

6. Phillips, CV. Commentary: Lack of scientific influences on epidemiology. International Journal of Epidemiology. 2008 Feb;37(1):59-64; discussion 65-8.

7. Libin, K. Whither the campus radical? Academic Freedom. National Post. October 1, 2007.


Our conflict of interest statement submitted with this was — as has long been my practice — an actual recounting of our COIs, unlike anything Glantz or anyone in tobacco control would ever write. It read:

The authors have experienced a history of attacks by those, like Glantz, who wish to silence heterodox voices in the area of tobacco research; our attackers have included people inside the academy (particularly the administration of the University of Alberta School of Public Health (National Post, 2007)), though not Glantz or his immediate colleagues as far as we know. The authors are advocates of enlightened policies toward tobacco and nicotine use, and of improving the conduct of epidemiology, which place us in political opposition to Glantz and his colleagues. The authors conduct research on tobacco harm reduction and receive support in the form of a grant to the University of Alberta from U.S. Smokeless Tobacco Company; our research would not be possible if Glantz et al. succeeded in their efforts to intimidate researchers and universities into enforcing their monopoly on funding. Unlike the grant that supported Glantz’s research, our grant places no restrictions on the use of the funds, and certainly does not pre-ordain our conclusions. The grantor is unaware of this letter, and thus had no input or influence on it. Dr. Phillips has consulted for U.S. Smokeless Tobacco Company in the context of product liability litigation and is a member of British American Tobacco’s External Scientific Panel.

Glantz responds to his (other) critics, helping make my point

by Carl V Phillips

Yesterday, I explained what was fundamentally wrong with Stanton Glantz’s new “meta-analysis” paper, beginning with parody and ending with a lament about the approach of his critics who are within public health. Glantz posted a rebuttal to the press release from those critics on his blog, which does a really nice job of helping me make some of my points. I look forward to his attempt to rebut my critique (hahaha — like he would dare), which would undoubtedly help me even more.

Glantz pretty well sums it up with:

The methods and interpretations in our paper follow standard statistical methods for analyzing and interpreting data.

Continue reading

The bright side of new Glantz “meta-analysis”: at least he left aerospace engineering

by Carl V Phillips

Stanton Glantz is at it again, publishing utter drivel. Sorry, that should be taxpayer-funded utter drivel. The journal version is here and his previous version on his blog here. I decided to rewrite the abstract, imagining that Glantz had stayed in the field he apparently trained in, aerospace/mechanical engineering. (For those who do not get the jokes, read on — I explain in the analysis. Clive Bates already explained much of this, but I am distilling it down the most essential problems and trying to explain them so the reasons for them are apparent and this is not just a battle of assertions.) Continue reading

Sunday Science Lesson: Identifying bullshit is usually easy (it just seldom happens in tobacco-land)

by Carl V Phillips

In the previous post, I quoted from Jon Stewart’s farewell monologue in which he alluded to how it is usually relatively easy to identify utterly bullshit claims and call them out. This includes utterly junk science. There are stories of master fraudsters in science, who carefully cook data and convince the world for years they have made game-changing discoveries, only getting caught after too much contrary evidence piles up. For some immediately detectable cases of junk science, it requires a bit of clever expert analysis to detect it. But these cases should not distract from the fact that most junk science is junk on its face. Continue reading

Dear @FDATobacco: Stanton Glantz’s junk science reflects upon you

by Carl V Phillips

Dear FDA Center for Tobacco Products:

I know you did not create Stanton Glantz. His intense barrage of patently absurd junk science predates your existence. You did not cause him to become the combination of utterly innumerate and/or sociopathic (it has always been difficult to be sure how much his utter disregard for real science is explained by each of these). But you own him now, thanks to the fact that you fund him and his minions, and so his nonsense is now on you. You claim to be about science. Are you? Continue reading

What is peer review really? (part 8 – the case of Borderud et al.)

by Carl V Phillips

A few months ago, Borderud, Li, Burkhalter, Sheffer, and Ostroff, from Memorial Sloan-Kettering Cancer Center published a paper in the peer-reviewed journal, Cancer, that they claimed showed that using e-cigarettes did not help — and indeed hindered — attempts to quit smoking by cancer patients who enrolled in a smoking cessation program. The problem is that it showed no such thing. Instead, what is shows quite clearly is just how bad journal peer review really is in this field. Continue reading